Clearside Biomedical (CLSD) Issues Earnings Results, Misses Expectations By $0.13 EPS

Clearside Biomedical (NASDAQ:CLSD) announced its quarterly earnings results on Tuesday. The company reported ($0.68) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.13), Morningstar.com reports. The company had revenue of $0.03 million during the quarter.

Shares of CLSD stock opened at $1.37 on Thursday. Clearside Biomedical has a 52 week low of $0.99 and a 52 week high of $15.33. The firm has a market capitalization of $44.83 million, a P/E ratio of -0.51 and a beta of -1.13. The company has a quick ratio of 4.59, a current ratio of 4.59 and a debt-to-equity ratio of 0.22.

A number of hedge funds have recently made changes to their positions in CLSD. Alps Advisors Inc. lifted its position in Clearside Biomedical by 22.3% during the third quarter. Alps Advisors Inc. now owns 56,670 shares of the company’s stock valued at $349,000 after buying an additional 10,315 shares during the period. Rhumbline Advisers lifted its position in Clearside Biomedical by 48.5% during the fourth quarter. Rhumbline Advisers now owns 36,979 shares of the company’s stock valued at $40,000 after buying an additional 12,076 shares during the period. Geode Capital Management LLC lifted its position in Clearside Biomedical by 4.9% during the fourth quarter. Geode Capital Management LLC now owns 303,512 shares of the company’s stock valued at $324,000 after buying an additional 14,181 shares during the period. Bank of America Corp DE lifted its position in Clearside Biomedical by 915.6% during the second quarter. Bank of America Corp DE now owns 16,574 shares of the company’s stock valued at $177,000 after buying an additional 14,942 shares during the period. Finally, Marshall Wace North America L.P. lifted its position in Clearside Biomedical by 2.8% during the third quarter. Marshall Wace North America L.P. now owns 582,625 shares of the company’s stock valued at $3,583,000 after buying an additional 15,916 shares during the period. 39.93% of the stock is owned by institutional investors.

A number of brokerages recently commented on CLSD. Zacks Investment Research raised Clearside Biomedical from a “hold” rating to a “buy” rating and set a $1.25 price target for the company in a research note on Thursday, January 3rd. ValuEngine lowered Clearside Biomedical from a “buy” rating to a “hold” rating in a research note on Thursday, January 24th. Finally, Cowen reaffirmed a “hold” rating on shares of Clearside Biomedical in a research note on Tuesday, January 22nd. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and five have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $10.32.

ILLEGAL ACTIVITY NOTICE: This story was posted by WKRB News and is owned by of WKRB News. If you are viewing this story on another publication, it was illegally stolen and republished in violation of U.S. & international trademark & copyright law. The correct version of this story can be viewed at https://www.wkrb13.com/2019/03/14/clearside-biomedical-clsd-issues-earnings-results-misses-expectations-by-0-13-eps.html.

Clearside Biomedical Company Profile

Clearside Biomedical, Inc, a late-stage clinical biopharmaceutical company, develops pharmacological therapies to treat blinding diseases of the eye. It is developing suprachoroidal injection of CLS-TA, a proprietary preservative-free formulation of the corticosteroid triamcinolone acetonide, which is in Phase III clinical trial for the treatment of macular edema associated with non-infectious uveitis; suprachoroidal injection of CLS-TA and a concomitant intravitreal injection of Eylea, an inhibitor of vascular endothelial growth factor that is in Phase III clinical trial to treat macular edema associated with retinal vein occlusion; and suprachoroidal injection of CLS-TA alone or together with intravitreal injection of Eylea that is in phase II clinical trial for diabetic macular edema.

See Also: Special Dividends

Earnings History for Clearside Biomedical (NASDAQ:CLSD)

Receive News & Ratings for Clearside Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.